List of Viibryd drug patents

Viibryd is owned by Allergan.

Viibryd contains Vilazodone Hydrochloride.

Viibryd has a total of 8 drug patents out of which 8 drug patents have expired.

Expired drug patents of Viibryd are:

  • US8236804
  • US8193195
  • US7834020*PED
  • US8193195*PED
  • US8236804*PED
  • US8673921*PED
  • US7834020
  • US8673921

Viibryd was authorised for market use on 21 January, 2011.

Viibryd is available in tablet;oral dosage forms.

Viibryd can be used as treatment of major depressive disorder (mdd).

The generics of Viibryd are possible to be released after 31 July, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7834020 ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(8 months ago)

US8673921 ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(8 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8236804 ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Jun, 2022

(8 months ago)

US8193195 ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(8 months ago)

US7834020

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(2 months ago)

US8193195

(Pediatric)

ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(2 months ago)

US8236804

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Dec, 2022

(2 months ago)

US8673921

(Pediatric)

ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(2 months ago)

Exclusivity Exclusivity Expiration
M Jan 31, 2023
Pediatric Exclusivity (PED) Jul 31, 2023

Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 January, 2011

Treatment: Treatment of major depressive disorder (mdd)

Dosage: TABLET;ORAL

How can I launch a generic of VIIBRYD before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in